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ProhormonesNon-synonymous mutations affecting both alleles of PCSK1 (proprotein convertase 1/3) are associated with
obesity and impaired prohormone processing. We report a proband who was compound heterozygous for
a maternally inherited frameshift mutation and a paternally inherited 474kb deletion that encompasses
PCSK1, representing a novel genetic mechanism underlying this phenotype. Although pro-vasopressin is
not a known physiological substrate of PCSK1, the development of central diabetes insipidus in this proband
suggests that PCSK1 deﬁciency can be associated with impaired osmoregulation.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
Proprotein convertases (PCs) are a family of serine endoproteases
that cleave inactive pro-peptides into biologically active peptides [1].
Two family members, Proprotein Convertase Subtilisin/Kexin types 1
and 2 (PCSK1 and PCSK2) are selectively expressed in neuroendocrine
tissues where they cleave a broad but speciﬁc set of prohormones
including pro-opiomelanocortin (POMC), prothyrotrophin releasing
hormone (TRH), proinsulin, proglucagon, and progonadotrophin
releasing hormone (GnRH) [2–9]. Congenital deﬁciency of PCSK1
has previously been reported in three unrelated probands with severe
hyperproinsulinemia, malabsorptive diarrhea, hypogonadotropic
hypogonadism, partial central defects in the adrenal and thyroid
axes and severe obesity [10–12]. At least some of these phenotypes
can be explained by the known or suggested involvement of PCSK1
in the processing of proinsulin, proopiomelanocortin, proglucagon,
proGnRH and proTRH [1]. We describe the fourth patient with
PCSK1 deﬁciency whose phenotype, in addition to the above, included
central diabetes insipidus.
2. Research design and methods
Direct nucleotide sequencing of the PCSK1 gene was carried out
as previously reported [10]. SNP microarray analysis was performednc. Open access under CC BY-NC-SA licusing the Affymetrix 6.0 platform using 500 ng of total genomic DNA.
Data was analyzed using Affymetrix Genotyping Console Browser
v.3.01. Multiplex Ligation-independent Probe Ampliﬁcation (MLPA)
probes in the PCSK1 gene region (chr5:95751875-95774445) were
designed following MRC-Holland (The Netherlands) recommendations
(http://www.mlpa.com/) and sequences are available upon request.
MLPA Hybridization, ligation and PCR were carried out using 200 ng of
genomic DNA and the SALSA-MLPA kit (MRC-Holland, TheNetherlands),
according to the manufacturer's instructions. The MLPA PCR products
(1 μl) were mixed with 0.5 μl GeneScan™-500 ROX™ size standard
(Applied Biosystems, UK) and 10 μl of HiDi formamide (Applied
Biosystems, UK) and separated on an ABI 3130 genetic analyzer (Applied
Biosystems, UK) and electrophoresis data extracted using GeneMapper
software v4.0 (Applied Biosystems, UK).3. Results
The male proband weighed 3.8 kg at birth. Diarrhea began at
three days of life and persisted despite oral feeding with multiple
formula changes. Endoscopy and ﬂexible sigmoidoscopy revealed
a grossly normal esophagus, stomach and duodenum, and scattered
ulcers in the sigmoid colon. Pathology reported eosinophils present
in the duodenum, stomach and colon and eosinophilic cryptitis
in the colon consistent with “allergic colitis”. Due to continued
diarrhea and failure to thrive, parenteral nutrition together with
continuous nasogastric feeds of an amino-acid based formula
was instituted at 2 months of age. Watery diarrhea, however,
continued. At 3 months the patient was admitted for sepsis associ-
ated with his intravenous catheter. Within 2 h of central lineense.
Fig. 1. A. Growth chart of proband demonstrating marked failure to thrive over ﬁrst 2
months; stabilization of weight gain from 2 months (with introduction of parenteral
nutrition and an amino acid based formula) and excessive weight gain from 1 year.
B. Family tree with chromatograms. Wildtype (Wt); deletion (del). C. MLPA conﬁrma-
tion of 474kb deletion of 5q15-q15 (95669703-96143955). Patient's MLPA traces are
in red overlayed on the control MLPA traces in black. MLPA probes for genes in the
region of interest are detailed below. Two of the MLPA probes are positioned within
the PCSK1 gene and appear to be deleted in the patient (arrows), and two are on either
side of the deleted region on chromosome 5q15 (distal and proximal probes), and they
are identical to the normal control.
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cortisol of 11.60 μg/dl (normal > 18 μg/dl) and a normal growth
hormone (13.8 ng/ml). Thyroid function was consistent with
central hypothyroidism (TSH 1.60 μIU/ml) with free thyroxine
levels of 0.78 ng/dl (normal 0.9–1.8 ng/dl) and a low testosterone
(28 ng/dl) and micropenis noted on clinical examination. In view
of these ﬁndings, he was diagnosed with partial hypopituitarism
and started on hydrocortisone and thyroxine replacement therapy.
Monthly testosterone injections for 3 months resulted in the
normalization of his penile size. Persistent polydipsia and polyuria
were noted in the third year of life. Following restriction of
ﬂuid overnight, his serum Na was 145 mEq/l, Cl 107 mEq/l and
osmolality was 304 mOsm/kg (urine speciﬁc gravity was 1.010
and osmolality 386 mOsm/kg), conﬁrming the diagnosis of diabe-
tes insipidus. He was started on oral desmopressin which led to
a marked improvement in symptoms and electrolyte abnormalities.
From 12 months, rapid weight gain began despite an apparent
average caloric intake of ~70 kcal/kg/day. Some solid foods were
introduced for the ﬁrst time at about 14 months, and this resulted in
improved stool consistency and less frequent diarrhea. By 24 months
old, the childwas grossly obese (Fig. 1A). The amino-acid based formula
was discontinued at 3 years of age.
In view of the combination of chronic diarrhea, rapid weight
gain and selective hypopituitarism, the possibility of PCSK1 deﬁ-
ciency was entertained. A nonfasting plasma insulin was low
(0.2 μU/ml) but proinsulin was >200 μU/ml. Direct nucleotide
sequencing of PCSK1 revealed an apparently homozygous single
base pair deletion which results in a frameshift after Pro 341, with
the introduction of 91 abnormal amino acids terminating in a
premature stop codon (W342GfsX92). The mutation is located
within a region that encodes the catalytic domain and thus would
be expected to abolish PCSK1 function. The proband's mother
was found to be heterozygous for the same mutation. However,
no PCSK1mutation was found in his father. SNP microarray analysis
revealed a 474kb interstitial deletion of 5q15-q15 (95669703-
96143955) which contains three genes, PCSK1, calpastatin and
endoplasmic reticulum aminopeptidase 1. This deletion was con-
ﬁrmed by Multiplex Ligation-independent Probe Ampliﬁcation
(MLPA) and was also found in the patient's father (Figs. 1B and C).
Thus, the patient had inherited a large deletion that encompassed
the PCSK1 gene and also a frameshift mutation within the gene
resulting in the loss of both alleles and the phenotype of PCSK1
deﬁciency. Common heterozygous variants in PCSK1 have been
associated with late-onset obesity [13]. However, both parents
of this proband were of normal weight and had no evidence of
intestinal or endocrine abnormalities. While these ﬁndings do not
preclude a more subtle effect of some PCSK1 variants on body
weight, the loss of both PCSK1 alleles appears to be necessary for
the complete phenotype.
4. Discussion
We describe the fourth patient with PCSK1 deﬁciency due to the
combination of a maternally inherited frameshift mutation leading
to a premature stop and a paternal deletion on chromosome 5
encompassing PCSK1 and two adjacent genes. This patient differs
signiﬁcantly from the three previous cases all of which involved ho-
mozygosity or compound heterozygosity for missense or splice site
mutations [10–12]. In this case one allele was deleted and the other
disrupted by a 91 amino acid insertion followed by a premature
stop codon occurring within the catalytic domain. While some
residual PCSK1 enzymatic activity could conceivably have persisted
in the three previously reported cases it seems highly likely that
this patient represents the null phenotype of PCSK1.
The development of central diabetes insipidus in our patient
suggests that PCSK1 may be involved in the full functioning or centralsensing of osmolality in humans. Whether this is due to the failure of
provasopressin processing or to some other malfunction of osmo-
reception or vasopressin production or release is unknown. Vasopres-
sin is synthesized in hypothalamic neurons expressing both PCSK1
and PCSK2 [5]. In mice, both PCSK1 and PCSK2 are involved in the
processing of pro-vasopressin to vasopressin, suggesting that a degree
of redundancy may exist in vivo [6,14,15]. In summary we report the
fourth patient with PCSK1 deﬁciency. The ﬁnding of diabetes insipidus
in this patient, and clinical features suggestive of this diagnosis in one
patient previously reported by us [12], suggest that this potentially
clinically signiﬁcant and treatable abnormality should be sought in
future patients presenting with this syndrome.
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